Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.38 |
| ▸ | HTR2C | P28335 | 6/20 | 0.38 |
| ▸ | HTR1A | P08908 | 6/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 4/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | MLNR | O43193 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6709392 | 0.82 | FEN1 (0.43) | SLC6A2SLC6A4HTR2CHTR1ASLC6A3 | |
| SCHEMBL5937367 | 0.81 | HTR2C (0.45) | SLC6A2SLC6A4HTR2CHTR1ASLC6A3 | |
| SCHEMBL6791079 | 0.79 | KDM4E (0.37) | — | |
| SCHEMBL5899888 | 0.79 | SLC6A2 (0.62) | SLC6A2SLC6A4HTR1ASLC6A3HTR6 | |
| SCHEMBL6796355 | 0.77 | SLC6A4 (0.39) | SLC6A4 | |
| SCHEMBL6790396 | 0.74 | DRD2 (0.39) | — | |
| SCHEMBL5899857 | 0.74 | MEN1 (0.36) | SLC6A2SLC6A4HTR2CHTR1ASLC6A3 | |
| SCHEMBL6784310 | 0.72 | HTR1A (0.45) | HTR1A | |
| SCHEMBL6709364 | 0.71 | HTR2C (0.42) | HTR2C | |
| SCHEMBL2608857 | 0.66 | RXRA (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147557-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | BOUILLOT ANNE (FR) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147557-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | NR1H2, NR1H3, NR1H4 | SLC6A2 2350/4885SLC6A4 969/4885HTR2C 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.